natgillin/translations-raw huggingface dataset:
O prehodu skozi placento je na voljo le malo podatkov iz študij na živalih (glejte poglavje 4.6).
Only limited data from animal studies are available regarding the placental transfer (see section 4.6).
O prehodu skozi placento je na voljo le omejena količina podatkov, pridobljenih v študijah na živalih (glejte poglavje 5.3).
Only limited data from animal studies are available regarding the placental transfer (see section 5.3).
O prekinitvi zdravljenja je treba razmisliti tudi v primeru, če so simptomi v mišicah hudi in motijo dnevne dejavnosti (ne glede na to, kakšne so vrednosti kreatin-fosfokinaze).
Treatment discontinuation should also be considered if the muscular symptoms are severe and cause daily discomfort (whatever CK levels).
O preobčutljivostnih reakcijah, vključno z izpuščajem, urtikarijo, angioedemom in anafilaktičnimi reakcijami so poročali redko.
Hypersensitivity reactions including rash, urticaria, angioedema and anaphylactic reactions have been reported rarely.
O sekundarnem prenosu okužb z živimi cepivi pri bolnikih, ki prejemajo zdravilo STELARA ni podatkov.
No data are available on the secondary transmission of infection by live vaccines in patients receiving STELARA.
O srčnem popuščanju so pri bolnikih, ki so se zdravili s pramipeksolom, poročali v kliničnih študijah in v obdobju po začetku trženja.
In clinical studies and post-marketing experience cardiac failure has been reported in patients with pramipexole.
O Taiwan 3/97 & SAT2 Saudi Arabia
A24 Cruzeiro and SAT2 Saudi Arabia
O Taiwan 3/97 and A Turkey 14/98
O Taiwan 3/97 and A22 Iraq
O Taiwan 3/97 and A Turkey 14/98 and Asia1 Shamir
O Taiwan 3/97, A24 Cruzeiro and A Turkey 14/98
O Taiwan 3/97 and A22 Iraq
O1 BFS and A Turkey 14/98
O Taiwan 3/97 and A22 Iraq and A24 Cruzeiro
O1 BFS, A24 Cruzeiro and Asia1 Shamir
O Taiwan 3/97 and A22 Iraq and Asia1 Shamir
O1 BFS, A Turkey 14/98 and Asia1 Shamir
O Taiwan 3/97 and A24
O Taiwan 3/97, A22 Iraq and A24 Cruzeiro
O Taiwan 3/97 and Asia1 Shamir
O Taiwan 3/97 and A24 Cruzeiro
O Taiwan 3/97, Asia1 Shamir & SAT2 Saudi Arabia
O Taiwan 3/97, Asia1 Shamir and SAT2 Saudi Arabia
O Taiwan 3/97............................................................................................................................≥ 6 PD50*
O Taiwan 3/97........................................................................................................................... ≥ 6 PD50
O tem odlogu motoričnih zapletov pri pramipeksolu je treba presoditi glede na večje izboljšanje motorične funkcije pri levodopi (izmerjeno s srednjo spremembo pri klinični nevrološki preiskavi za bolnike s Parkinsonovo boleznijo – po lestvici UPDRS).
This delay in motor complications with pramipexole should be balanced against a greater improvement in motor function with levodopa (as measured by the mean change in UPDRS-score).
O tem se boste pogovorili s svojim zdravnikom, ki vas bo seznanil z možnimi tveganji in koristmi tega zdravljenja.
Your doctor will discuss this with you and will explain the possible risks and benefits of the treatment.
O tem, ali prekinitev zdravljenja z difosfonatom zmanjša tveganje za osteonekrozo čeljustnic pri bolnikih, ki potrebujejo zobozdravstvene posege, ni podatkov.
For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw.
O trombotični trombocitopenični purpuri (TTP) so po uporabi klopidogrela poročali zelo redko, včasih po kratki izpostavljenosti.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
O uporabi pemetrekseda pri bolnikih z očistkom kreatinina, nižjim od 45 ml/min, ni zadostnih podatkov; zato uporabe pemetrekseda ne priporočamo (glejte poglavje 4.4).
There are insufficient data on the use of pemetrexed in patients with creatinine clearance below 45 ml/min; therefore, the use of pemetrexed is not recommended (see section 4.4).
O uporabi zoledronske kisline pri nosečnicah ni dovolj podatkov.
There are no adequate data on the use of zoledronic acid in pregnant women.
O vývoji rezistence na atazanavir posílený kobicistatem jsou k dispozici pouze omezené údaje.
Limited data are available on the development of resistance to atazanavir boosted with cobicistat.
O zdravljenju moramo ponovno presoditi, če se po 5 dneh klinično stanje ne izboljša.
The treatment should be re-considered if at 5 days no improvement in the clinical condition is observed.
O zdravljenju moramo ponovno presoditi, če se po 5 dneh klinično stanje ne izboljša.
The treatment should be reconsidered if at 5 days no improvement in the clinical condition is observed.
o če imajo odprtino (fistulo) med požiralnikom in dihalnimi potmi. o če imajo razjedo (erozijo) velikih krvnih žil.
o they have trachea or broncho-oesophageal fistulas. o they have suspected erosions of major blood vessels.
o če imate porfirijo,
if you have porphyria
o Иглата е покрита от предпазителя на иглата и няма да се вижда (вижте Фигура И).
o The needle is covered by the needle cover and the needle will not be seen (See Figure I).
o Не разклащайте предварително напълнената писалка.
o Do not shake the pre-filled pen.
o Не разклащайте предварително напълнената спринцовка.
o Do not shake the pre-filled syringe.
o Необходимост от пълна кръвна картина преди употреба и наблюдение в клинично подходящи интервали
Need for full blood count prior to use and monitoring at clinically appropriate intervals
o Необходимостта да се понижи дозата с 10 mg/kg, ако серумния креатинин се повишава:
The need to reduce by 10 mg/kg the dose if serum creatinine rises:
o Необходимостта да се прекъсне лечението след намаляване на дозата, ако серумният креатинин се повишава:
The need to interrupt treatment after a dose reduction if serum creatinine rises:
o вече не е разрешен за употреба
Tabulated list of adverse reactions
o вече не е разрешен за употреба o вече не е разрешен за употреба
no longer authorised no longer authorised
o включително гръдна болка и стягане в гърдите п Това е дословен термин.
o including chest pain and chest tightness p This is a verbatim term.
o нестероидни противовъзпалителни лекарства, обичайно използани за лечение на болезнени и/или възпалителни състояния на мускулите или ставите,
a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscles or joints
o перорални антикоагуланти, лекарства, използвани за намаляване съсирваемостта на кръвта
oral anticoagulants, medicines used to reduce blood clotting
o приложение Подкожно
use Subcutaneous
o тиклопидин, друго антитромбоцитно лекарство,
ticlopidine, other antiplatelet agent
o хепарин или друго лекарство за инжектиране, използвано за намаляване съсирването на кръвта,
heparin or any other injectable medicine used to reduce blood clotting
O-глюкурониди на топотекан и N-десметил топотекан са установени в урината.
O-glucuronides of both topotecan and N- desmethyl topotecan have been identified in the urine.
O1 BFS
Asia1 Shamir
O1 BFS &
AFTOVAXPUR DOE
O1 BFS and A Turkey 14/98
O1 BFS and A22 Iraq
O1 BFS and A Turkey 14/98 and Asia1 Shamir
O1 BFS, A24 Cruzeiro and A Turkey 14/98
O1 BFS and A22 Iraq and A24 Cruzeiro
O1 BFS, O Taiwan 3/97 and A Turkey 14/98
O1 BFS and A22 Iraq and Asia1 Shamir
O1 BFS, O Taiwan 3/97 and Asia1 Shamir
O1 BFS and O Taiwan 3/97
O1 Manisa and Asia1 Shamir
O1 BFS and O Taiwan 3/97 and A Turkey 14/98
O1 BFS, O Taiwan 3/97 and A22 Iraq
O1 BFS and O Taiwan 3/97 and A22 Iraq
O1 Manisa, A24 Cruzeiro and Asia1 Shamir
O1 BFS and O Taiwan 3/97 and Asia1 Shamir
O1 BFS, O Taiwan 3/97 and A24 Cruzeiro
O1 BFS,
AFTOVAXPUR DOE
O1 Manisa ..................................................................................................................................≥ 6 PD50*
O1 Manisa .................................................................................................................................≥ 6 PD50
O1 Manisa and O Taiwan 3/97 and A Turkey
O1 Manisa, O Taiwan 3/97 and A22 Iraq
O1 Manisa and O Taiwan 3/97 and A24
O1 Manisa, O1 BFS and Asia1 Shamir
O1 Manisa and O Taiwan 3/97 and Asia1 Shamir
O1 Manisa, O Taiwan 3/97 and A24 Cruzeiro
O1 Manisa and O1 BFS and
A24 Cruzeiro and Asia 1 Shamir
O1 Manisa and O1 BFS and
O1 Manisa, O1 BFS and A22 Iraq
O1 Manisa and O1 BFS and
O1 Manisa, O1 BFS and O Taiwan 3/97
O1 Manisa, A Turkey 14/98 & SAT2 Saudi Arabia
O1 Manisa, Asia1 Shamir and SAT2 Saudi Arabia
O1 Manisa, A22 Iraq & SAT2 Saudi Arabia
O1 Manisa, A24 Cruzeiro and SAT2 Saudi Arabia
O1 Manisa, Asia1 Shamir & SAT2 Saudi Arabia
O1 BFS, O Taiwan 3/97 and SAT2 Saudi Arabia
O1 Manisa, O Taiwan 3/97 & SAT2 Saudi Arabia
O1 Manisa, A22 Iraq and SAT2 Saudi Arabia
O3HA1.EHl1.s BbPXY OnAKOBKATA l1 JIl1CTOBKATA
LABELLING AND PACKAGE LEAFLET
O6.sB.sBAHE HA AKTl1BHOTO BEW,ECTBO
STATEMENT OF ACTIVE SUBSTANCE
Oakbank Park Road, Livingston EH53 0TG Обединеното кралство
Oakbank Park Road Livingston EH53 0TG United Kingdom
OASIS 6 e двойно-сляпо, рандомизирано изпитване, оценяващо безопасността и ефикасността на фондапаринукс 2,5 mg веднъж дневно спрямо обичайна терапия (плацебо (47%) или нефракциониран хепарин (53%)) при приблизително 12 000 пациенти с миокарден инфаркт с елевация на ST-сегмента.
OASIS 6 was a double blind, randomised study assessing the safety and efficacy of fondaparinux 2.5 mg once daily, versus usual care (placebo (47%) or UFH (53%) in approximately 12,000 patients with STEMI.
OASIS 6 e двойно-сляпо, рандомизирано изпитване, оценяващо безопасността и ефикасността на фондапаринукс 2,5 mg веднъж дневно спрямо обичайна терапия (плацебо (47%) или нефракциониран хепарин(53%)) при приблизително 12 000 пациенти с миокарден инфаркт с елевация на ST-сегмента.
OASIS 6 was a double blind, randomised study assessing the safety and efficacy of fondaparinux 2.5 mg once daily, versus usual care (placebo (47%) or UFH (53%)) in approximately 12000 patients with STEMI.
OATP/BCR
EFFECT
OATP1B и CYP3A)
inhibition)
OATP1B/B
0.83
OATP1B1 kobicistatem.
transporter OATP1B1 by
OATP1B1/3 и MRP2 участват в транспортирането на билирубин във и от хепатоцитите.
OATP1B1/3 and MRP2 are involved in the transport of bilirubin into and out of hepatocytes.
Oavsiktlig självinjektion kan orsaka smärta.
Accidental self-injection may give rise to pain.
Ob ekstravazaciji ukrepajte skladno z lokalno ustaljeno prakso kot pri drugih učinkovinah, ki niso mehurjevci.
Extravasation should be managed by local standard practice as with other non-vesicants.
Ob hudi nevtropeniji so med prvim ciklom zdravljenja pri 16 % bolnikov opazili zvišano telesno temperaturo ali različne okužbe, 23 % bolnikov pa je imelo takšne neželene učinke ves čas (6 % ciklov zdravljenja).
In association with severe neutropenia, fever or infection occurred in 16 % of patients during course 1 and overall in 23 % of patients (6 % of courses).
Ob hudi nevtropeniji so med prvim ciklom zdravljenja pri 16 % bolnikov opazili zvišano telesno temperaturo ali različne okužbe, 23 % bolnikov pa je imelo takšne neželene učinke ves čas (6 % ciklov zdravljenja).
In association with severe neutropenia, fever or infection occurred in 16% of patients during course 1 and overall in 23 % of patients (6 % of courses).
Ob izvedbi primarne analize je mediana spremljanja glede celokupnega preživetja pri celotni skupini bolnikov znašala 18,3 meseca.
At the time of primary analysis, the median follow-up for overall survival in the full analysis set was 18.3 months.
Ob naključnem stiku zdravila s kožo ali z očmi morate le-to takoj sprati z velikimi količinami vode.
Accidental contact with the skin or eyes should be treated immediately with copious amounts of water.
ob r
(2.1 - 2.9)
Ob stalno manjši aktivnosti encima CYP2A6 pri azijskih bolnikih je bila vrednost AUC0-12 za tegafur višja, čas t1/2 pa daljši v azijski skupini v primerjavi s kavkaško skupino.
Consistent with the lower CYP2A6 activity in the Asian patients, tegafur AUC0-12 was higher and T1/2 was longer in the Asian group compared to the Caucasian group.
ob uporabi mora biti ventil do konca odprt, vendar ga ne odpirajte na silo okvarjenega ventila ne uporabljajte in ne popravljajte.
the valve should be fully open when used but not be opened with violence a defective valve should neither be used nor be repaired.
Ob upoštevanju kontraindikacije za pravastatin med dojenjem je tudi zdravilo Pravafenix med dojenjem kontraindicirano (glejte poglavje 4.3).
Therefore, taking into account the contra indication of pravastatin during lactation, Pravafenix is contraindicated during breastfeeding (see section 4.3).
Ob uvedbi naknadnih ciklov zdravljenja
At the initiation of subsequent cycles of treatment
Ob uvedbi zdravila Zoledronska kislina Actavis pri bolnikih z multiplim mielomom ali metastatskimi kostnimi lezijami zaradi parenhimskih tumorjev je treba določiti serumski kreatinin in očistek kreatinina (CLcr).
When initiating treatment with Zoledronic acid Actavis in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined.
Ob vnaprej določeni meji ne-manjvrednosti, ki je bila -10 %, je bil Mantel- Haenszlov statistični ne-manjvrednostni interval zaupanja s prilagojeno stratifikacijo za razliko v primarnem kriteriju, popolnem odgovoru (CR), [-10,5, 1,7 %], kar pomeni, da ne-manjvrednost ni bila dokazana.
Given the pre-specified non- inferiority margin of -10%, the stratum adjusted Mantel-Haenszel statistical non-inferiority confidence interval for the difference in the primary endpoint, complete response (CR), was [-10.5, 1.7%], therefore non-inferiority was not demonstrated.
Ob zmanjšanem delovanju ledvic se je uravnotežena izpostavljenost za 5-FU povečala.
As renal function decreased, there was an increase in 5-FU steady state exposure.
Oba sta normalna in vam ju ni treba odstraniti.
These are both normal and do not need to be removed
obabi r
5.0
obabi r
6.1
Obal tobolky: želatina, indigokarmín (E132), oxid titaničitý (E171), natrium-lauryl-sulfát, sorbitan-laurát, černý inkoust (šelak, černý oxid železitý (E172), propylenglykol).
Capsule shell: gelatin, indigo carmine (E132), titanium dioxide (E171), sodium laurilsulfate, sorbitan monolaurate, black ink (shellac, iron oxide black (E172), propylene glycol).
obden/elvitegravir 150 mg jednou denně/kobicistat 150 mg jednou denně
day/elvitegravir 150 mg once daily/cobicistat 150 mg once daily
obdobja vznesenega razpoloženja ali občutki zaskrbljenosti
elevated moods or feelings of anxiousness
Obdobje zdravljenja v študiji je trajalo 12 mesecev; pred tem so bolniki opravili od 4- do 9-tedensko obdobje presejanja, med katerim so vsaj 2 tedna jemali vitamin D in dodatke elementarnega kalcija.
The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks.
OBIZUR 500 U прах и разтворител за инжекционен разтвор
OBIZUR 500 U powder and solvent for solution for injection
OBIZUR 500 U прах и разтворител за инжекционен разтвор сузоктоког алфа
OBIZUR 500 U powder and solvent for solution for injection susoctocog alfa
Obizur е разрешен за употреба при „извънредни обстоятелства”.
Obizur has been authorised under ‘exceptional circumstances’.
OBIZUR не влияе върху способността за шофиране и работа с машини.
OBIZUR has no influence on your ability to drive and use machines.
OBIZUR съдържа активното вещество сузоктоког алфа – антихемофилен фактор VIII, свинска последователност.
OBIZUR contains the active substance susoctocog alfa, antihaemophilic Factor VIII, porcine sequence.
OBIZUR съдържа натрий
OBIZUR contains sodium
OBIZUR, ПРУ трябва да осъществи програма за наблюдение/регистър според
conduct a surveillance programme/ registry according to an agreed protocol and for an
Običajni faktorji zaščite pred UV-žarki (ultravijoličnim sevanjem) so brez učinka pri zaščiti pred fotosenzitivnimi reakcijami, ker fotoaktivacijo povzroča vidna svetloba.
Conventional UV (ultraviolet) sunscreens are of no value in protecting against photosensitivity reactions because photoactivation is caused by visible light.
Običajni odmerek je 0,75 mg na m2 telesne površine enkrat na dan tri dni.
The usual dose is 0.75 mg per m2 of body surface area once daily for 3 days.
Običajni odmerek je 1,5 mg na m2 telesne površine enkrat na dan pet dni.
The usual dose is 1.5 mg per m2 of body surface area once daily for 5 days.
Običajni odmerek za prvi teden zdravljenja je 1 tableta zdravila Pramipeksol Accord po 0,088 mg 3-krat na dan (0,264 mg na dan):
During the first week, the usual dose is 1 tablet Pramipexole Accord 0.088 mg three times a day (equivalent to 0.264 mg daily):
Običajni posamezni odmerek je 4 mg.
The usual single dose given is 4 mg.
Običajni vzdrževalni odmerek je 1,1 mg na dan.
The usual maintenance dose is 1.1 mg per day.
Objem (ml) = BSA (m2) x individuálna dávka (mg/m2)
Volume (ml) = BSA (m2) x individual dose (mg/m2)
Objeví-li se u těchto pacientů známky zhoršování jaterního onemocnění, musí být zváženo přerušení nebo ukončení léčby.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.
Obs: För att bevara produktens sterilitet är det viktigt att nålen för att lätta på trycket inte förs in genom flaskans försegling innan produkten lösts upp.
Note: to preserve product sterility, it is important that the gas relief needle is not inserted through the vial closure before the product is dissolved.
Obsah balenia a ďalšie informácie
Contents of the pack and other information
Obsah balenia a ďalšie informácie Čo Yondelis obsahuje:
Contents of the pack and other information What Yondelis contains:
Obsah balení a další informace Co alli obsahuje
Contents of the pack and other further information What alli contains
Obsah balení a další informace Co alli obsahuje
Contents of the pack and other information What alli contains
Obsah balení a další informace Co EVOTAZ obsahuje
Contents of the pack and other information What EVOTAZ contains
Obsah balení a další informace Co přípravek obsahuje
Contents of the pack and other information What Intuniv contains
OBSAH LÉČIVÉ LÁTKY/LÁTEK
STATEMENT OF ACTIVE SUBSTANCE(S)
OBSAH LÉČIVÉ LÁTKY/LÉČIVÝCH LÁTEK
STATEMENT OF ACTIVE SUBSTANCE(S)
OBSAH V HMOTNOSTNÝCH, OBJEMOVÝCH ALEBO V KUSOVÝCH JEDNOTKÁCH
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
Obsahuje laktosu a sacharosu.
Contains lactose and sucrose.
Obsahuje také laktosu.
Also contains lactose.
Obstaja veliko vrst NSAID-ov z različnimi trajanji delovanja.
There are many sorts of NSAIDs with different durations of activity.
Obstajajo dokazi, da zdravljenje s fibrati lahko zmanjša dogodke povezane s koronarno boleznijo srca, ni pa dokazov, da fibrati zmanjšajo umrljivost zaradi vseh vzrokov pri primarni ali sekundarni preventivi kardiovaskularnih bolezni.
There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease.
OBT: Оптимизирана Основна Терапия
OBT: Optimised Background Therapy
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali ali pa boste morda začeli jemati katero zdravilo.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali farmacevta, če uporabljate ali ste pred kratkim uporabljali katero koli zdravilo, tudi če ste ga dobili brez recepta.
Tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika, če jemljete ali ste pred kratkim jemali katero od naslednjih zdravil:
Talk to your doctor if you are using or have recently used any of the following medicines:
Obvestite svojega zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Obvestite svojega zdravnika, če opazite vi ali vaša družina/negovalec, da se pri vas razvija nagib ali želja po vedenju, ki za vas ni običajno, in se ne morete upreti impulzu, težnji ali skušnjavi po dejanjih, ki bi lahko škodila vam ali drugim.
Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others.
Obvestite svojega zdravnika, če se pojavi kar koli od naštetega:
Tell your doctor if any of the following applies to you:
Obvestite svojega zdravnika, če se pojavijo hud izpuščaj, srbenje ali mehurčki (Stevens-Johnsonov sindrom ali toksična epidermalna nekroliza).
Contact your doctor if you get a severe rash, or itching, or blistering (Stevens-Johnson syndrome or toxic epidermal necrolysis).
Obvestite svojega zdravnika, če ste imeli ali se je pri vas razvila katerakoli bolezen, zlasti izmed naslednjih:
Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following:
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, vključno z:
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including:
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Tell your doctor if you are taking , have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali ste morda jemali katerokoli zdravilo.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta:
Tell your doctor or pharmacist:
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali boste morda začeli jemati katero koli drugo zdravilo.
Tell your doctor if you are taking, have recently taken or might take any other medicines. .
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Tell your doctor if you are taking , have recently taken or might take any other medicines.
Obvestite zdravnika, če vi ali vaš otrok jemljete ali ste pred kratkim jemali ali uporabljali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Please tell your doctor if you (as the patient) or your child (as the patient) are taking or have recently taken or used any other medicines, including medicines obtained without a prescription.
Obvykle se objevily na začátku léčby (v průběhu 3 měsíců) a u většiny pacientů se vyskytla pouze jedna epizoda.
They generally occurred early in treatment (within 3 months) and most patients experienced only one episode.
Obézním pacientům byly navíc po dobu 6 měsíců podávány třikrát denně dávky 240 mg orlistatu.
In addition, doses of 240 mg three times daily have been administered to obese patients for 6 months.
Občasna uporaba acetilsalicilne kisline (ne več kot 1.000 mg v obdobju 24 ur) na splošno ne povzroča težav, vendar se morate v primeru dolgotrajne uporabe v drugih okoliščinah pogovoriti s svojim zdravnikom.
An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Občasne: Angina pektoris, atrijska fibrilacija, atrijska undulacija, pritisk v prsih
Uncommon: Angina pectoris, atrial fibrillation, atrial flutter, chest discomfort